Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma

被引：18

作者：

Chen, Guo ^{[1
]}

Davies, Michael A. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2014年 / 28卷 / 03期

关键词：

BRAF(V600); Melanoma; Drug resistance; MAPK; PI3K/AKT; Tumor heterogeneity; Combination therapy; BRAF INHIBITOR RESISTANCE; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; B-RAF; TUMOR MICROENVIRONMENT; CONFER RESISTANCE; IMPROVED SURVIVAL; MEK INHIBITORS; UP-REGULATION; MUTATIONS;

D O I：

10.1016/j.hoc.2014.03.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Although selective mutant BRAF inhibitors have revolutionized the treatment of metastatic melanoma, the magnitude and duration of their clinical benefit are significantly undermined by de novo and acquired resistance. Functional studies, molecular characterization of clinical samples, and clinical trials are providing insights into the landscape of resistance mechanisms in this disease. These findings have implications for the development of rational therapeutic approaches, and have identified several challenges that remain to be overcome if outcomes are to be improved in patients with metastatic melanoma.

引用

页码：523 / +

页数：15

共 63 条

[1]

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3 [J].

Abel, Ethan V. ;

Basile, Kevin J. ;

Kugel, Curtis H., III ;

Witkiewicz, Agnieszka K. ;

Le, Kaitlyn ;

Amaravadi, Ravi K. ;

Karakousis, Giorgos C. ;

Xu, Xiaowei ;

Xu, Wei ;

Schuchter, Lynn M. ;

Lee, Jason B. ;

Ertel, Adam ;

Fortina, Paolo ;

Aplin, Andrew E. .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (05) :2155-2168

[2]

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma [J].

Bollag, Gideon ;

Hirth, Peter ;

Tsai, James ;

Zhang, Jiazhong ;

Ibrahim, Prabha N. ;

Cho, Hanna ;

Spevak, Wayne ;

Zhang, Chao ;

Zhang, Ying ;

Habets, Gaston ;

Burton, ElizabethA. ;

Wong, Bernice ;

Tsang, Garson ;

West, Brian L. ;

Powell, Ben ;

Shellooe, Rafe ;

Marimuthu, Adhirai ;

Nguyen, Hoa ;

Zhang, Kam Y. J. ;

Artis, Dean R. ;

Schlessinger, Joseph ;

Su, Fei ;

Higgins, Brian ;

Iyer, Raman ;

D'Andrea, Kurt ;

Koehler, Astrid ;

Stumm, Michael ;

Lin, Paul S. ;

Lee, Richard J. ;

Grippo, Joseph ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

Chapman, Paul B. ;

Flaherty, Keith T. ;

Xu, Xiaowei ;

Nathanson, Katherine L. ;

Nolop, Keith .

NATURE, 2010, 467 (7315) :596-599

[3]

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function [J].

Boni, Andrea ;

Cogdill, Alexandria P. ;

Dang, Ping ;

Udayakumar, Durga ;

Njauw, Ching-Ni Jenny ;

Sloss, Callum M. ;

Ferrone, Cristina R. ;

Flaherty, Keith T. ;

Lawrence, Donald P. ;

Fisher, David E. ;

Tsao, Hensin ;

Wargo, Jennifer A. .

CANCER RESEARCH, 2010, 70 (13) :5213-5219

[4]

The causes and consequences of genetic heterogeneity in cancer evolution [J].

Burrell, Rebecca A. ;

McGranahan, Nicholas ;

Bartek, Jiri ;

Swanton, Charles .

NATURE, 2013, 501 (7467) :338-345

[5]

Carlino MS, 2014, MOL ONCOL

[6]

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[7]

Distinct sets of genetic alterations in melanoma [J].

Curtin, JA ;

Fridlyand, J ;

Kageshita, T ;

Patel, HN ;

Busam, KJ ;

Kutzner, H ;

Cho, KH ;

Aiba, S ;

Bröcker, EB ;

LeBoit, PE ;

Pinkel, D ;

Bastian, BC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2135-2147

[8]

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance [J].

Das Thakur, Meghna ;

Salangsang, Fernando ;

Landman, Allison S. ;

Sellers, William R. ;

Pryer, Nancy K. ;

Levesque, Mitchell P. ;

Dummer, Reinhard ;

McMahon, Martin ;

Stuart, Darrin D. .

NATURE, 2013, 494 (7436) :251-255

[9]

Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[10]

The Role of the PI3K-AKT Pathway in Melanoma [J].

Davies, Michael A. .

CANCER JOURNAL, 2012, 18 (02) :142-147

← 1 2 3 4 5 6 7 →